Social interaction can help cancer patients survive longer
Study highlights the importance of social interaction during chemotherapy. It can help patients live longer after treatment.
Social interaction during chemotherapy can affect how well cancer patients fare after treatment, according to a new study recently published in the journal Network Science.
Researchers at the National Human Genome Research Institute and the University of Oxford in the United Kingdom found that cancer patients are a little more likely to survive for five years or more after chemotherapy if they had social interaction during chemotherapy with other patients who also survived for five years or more. Patients were a little more likely to die in less than five years after chemotherapy when they interacted during chemotherapy with those who died in less than five years.
“People model behavior based on what’s around them,” Jeff Lienert, lead author in NHGRI’s Social and Behavioral Research Branch and a National Institutes of Health Oxford-Cambridge Scholars Program fellow. “For example, you will often eat more when you’re dining with friends, even if you can’t see what they’re eating. When you’re bicycling, you will often perform better when you’re cycling with others, regardless of their performance.”
Lienert wanted to see if the impact of social interaction extended to cancer patients undergoing chemotherapy. He lead the study along with adviser, Felix Reed-Tsochas, Ph.D., at Oxford’s CABDyN Complexity Centre at the Saïd Business School, Laura Koehly, Ph.D., chief of NHGRI’s Social and Behavioral Research Branch, and Christopher Marcum, Ph.D., a staff scientist also in the Social and Behavioral Research Branch at NHGRI.
The team determined that when patients were around those during chemotherapy who died in less than five years following chemotherapy, they had a 72 percent chance of dying within five years following their chemotherapy.
The five-year survival rate is the percentage of people who live at least five years after chemotherapy treatment is completed. For example, a five-year survival rate of 70 percent means that an estimated 70 out of 100 people are still alive five years after chemotherapy.
According to the study, the best outcome was when patients interacted with someone who survived for five years or longer: they had a 68 percent chance of dying within five years. The researchers’ model also predicted that if patients were isolated from other patients, they would have a 69.5 percent chance of dying within five years.
“A two percent difference in survival – between being isolated during treatment and being with other patients – might not sound like a lot, but it’s pretty substantial,” Lienert said. “If you saw 5,000 patients in nine years, that 2 percent improvement would affect 100 people.”
The researchers didn’t study why the difference occurred, but hypothesize that it may be related to stress response. “When you’re stressed, stress hormones such as adrenaline are released, resulting in a fight or flight response,” Lienert said. “If you are then unable to fight or fly, such as in chemotherapy, these hormones can build up.”
While the researchers also didn’t investigate the impact of visitors on cancer patients undergoing therapy, the effect would likely be similar, he said.
“Positive social support during the exact moments of greatest stress is crucial,” Lienert said. “If you have a friend with cancer, keeping him or her company during chemotherapy probably will help reduce their stress. The impact is likely to be as effective, and possibly more effective, than cancer patients interacting with other cancer patients.”
Findings were based on electronic medical records data from 2000 to 2009 from two major hospitals in the United Kingdom’s National Health Service. The researchers examined the total time a patient spent with the same patients undergoing chemotherapy and their five-year survival rate.
“Mr. Lienert’s research is the first to investigate, on a large scale, how social context in a treatment setting can play a significant role in disease outcomes,” said Koehly. “As cancer care moves more towards targeted therapies based on genomic tumor assessments, NHGRI is interested in understanding how these social environmental factors might impact treatment efficacy.”